NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02672358 2018-08-10
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
Novartis
Phase 2 Withdrawn